US2005129736A1PendingUtilityA1

Compositions and methods for treating or preventing diseases of body passageways

62
Assignee: UNIV BRITISH COLUMBIAPriority: May 24, 1996Filed: Oct 22, 2004Published: Jun 16, 2005
Est. expiryMay 24, 2016(expired)· nominal 20-yr term from priority
Inventors:William L. HunterLindsay Machan
A61P 31/04A61P 31/06A61P 35/00A61P 43/00A61P 9/00A61P 9/10A61P 27/02A61K 9/167A61K 9/0024A61K 9/1647A61P 13/08A61K 9/10A61P 15/00A61K 31/28A61P 13/02A61P 11/08A61P 11/00A61K 9/5192A61K 9/5138A61K 9/5031A61K 9/5146A61K 9/1635A61K 9/70A61P 13/00A61K 47/34A61K 9/1075A61K 9/1652A61K 31/337A61K 9/5153A61K 9/7007A61P 1/04A61K 9/12A61P 1/00A61K 31/00A61K 31/335A61K 33/24
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a therapeutic agent. Representative examples of therapeutic agents include anti-angiogenic factors, anti-proliferative agents, anti-inflammatory agents, and antibiotics.

Claims

exact text as granted — not AI-modified
1 . A method for treating a neoplastic disease associated with narrowing or obstruction of a body passageway, comprising delivering to an external portion of a body passageway in a patient in need thereof a therapeutically effective amount of an anti-neoplastic agent or a composition comprising an anti-neoplastic agent, such that the neoplastic disease is treated.  
     
     
         2 . The method of  claim 1  wherein the narrowing or obstruction is a tumor.  
     
     
         3 . The method of  claim 1  wherein the disease is a male reproductive tract disease.  
     
     
         4 . The method of  claim 3  wherein the male reproductive tract disease is testicular cancer, cancer of the epididymus, a tumor of the vas deferens, or prostatic cancer.  
     
     
         5 . The method of  claim 1  wherein the disease is a female reproductive tract disease.  
     
     
         6 . The method of  claim 5  wherein the female reproductive tract disease is auterine cancer, cervical cancer, vaginal cancer or a malignancy of the fallopian tubes.  
     
     
         7 . The method of  claim 1  wherein the disease is a gastrointestinal tract disease, a biliary tract disease, a urinary tract disease, or a respiratory tract disease.  
     
     
         8 . The method of  claim 1  wherein the body passageway is selected from the group consisting of an esophagus, a stomach, a duodenum, a small intestine, a large intestine, biliary tracts, a ureter, a bladder, and a urethra.  
     
     
         9 . The method of  claim 1  wherein the body passageway is selected from the group consisting of fallopian tubes, uterus, vagina, and vas deferens.  
     
     
         10 . The method of  claim 1  wherein the body passageway is selected from the group consisting of lacrimal ducts, trachea, bronchi, bronchiole, nasal airways, eustachian tubes, and an external auditory canal.  
     
     
         11 . The method of  claim 1  wherein the anti-neoplastic agent is an anti-proliferative agent.  
     
     
         12 . The method of  claim 1  wherein the anti-neoplastic agent is an anti-angiogenic factor.  
     
     
         13 . The method of  claim 1  wherein the anti-neoplastic agent disrupts microtubule function.  
     
     
         14 . The method of  claim 1  wherein the anti-neoplastic agent is paclitaxel or an analogue or derivative thereof.  
     
     
         15 . The method of  claim 1  wherein the anti-neoplastic agent is paclitaxel.  
     
     
         16 . The method of  claim 1  wherein the anti-neoplastic agent is an analogue or derivative of paclitaxel.  
     
     
         17 . The method of  claim 1  wherein the anti-neoplastic agent is estradiol.  
     
     
         18 . The method of  claim 1  wherein the anti-neoplastic agent is carboplatin.  
     
     
         19 . The method of  claim 1  wherein the anti-neoplastic agent is doxorubicin.  
     
     
         20 . The method of  claim 1  wherein the anti-neoplastic agent is 5-fluorouracil.  
     
     
         21 . The method of  claim 1  wherein the composition is biodegradable.  
     
     
         22 . The method of  claim 1  wherein the composition is non-biodegradable.  
     
     
         23 . The method of  claim 1  wherein the composition further comprises a polymer.  
     
     
         24 . The method of  claim 23  wherein the polymer is biodegradable.  
     
     
         25 . The method of  claim 23  wherein the polymer is non-biodegradable.  
     
     
         26 . The method of  claim 1  wherein the composition further comprises a copolymer of lactic acid and glycolic acid.  
     
     
         27 . The method of  claim 1  wherein the composition further comprises a poly(caprolactone).  
     
     
         28 . The method of  claim 1  wherein the composition further comprises a poly(lactic acid).  
     
     
         29 . The method of  claim 1  wherein the composition further comprises a copolymer of poly(lactic acid) and poly(caprolactone)  
     
     
         30 . The method of  claim 1  wherein the composition further comprises a poly(ethylene-vinyl acetate).  
     
     
         31 . The method of  claim 1  wherein the composition further comprises a polyester.  
     
     
         32 . The method of  claim 1  wherein the composition further comprises a polyurethane.  
     
     
         33 . The method of  claim 1  wherein the composition further comprises a polyanhydride.  
     
     
         34 . The method of  claim 1  wherein the composition further comprises a gelatin.  
     
     
         35 . The method of  claim 1  wherein the composition is in the form of a paste.  
     
     
         36 . The method of  claim 1  wherein the composition is in the form of a film.  
     
     
         37 . The method of  claim 1  wherein the composition is in the form of a spray.  
     
     
         38 . The method of  claim 1  wherein the composition comprises microspheres having an average size ranging from about 0.5 μm to 200 μm.  
     
     
         39 . The method of  claim 1  wherein the neoplastic agent or the composition comprising the neoplastic agent is administered percutaneously to the exterior surface of the body passageway.  
     
     
         40 . The method of  claim 1  wherein the neoplastic agent or the composition comprising the neoplastic agent is applied to the adventitial surface of the body passageway.  
     
     
         41 . A method for treating a neoplastic disease associated with narrowing or obstruction of a body passageway, comprising delivering to smooth muscle cells via the adventitia of a body passageway in a patient in need thereof a therapeutically effective amount of an anti-neoplastic agent or a composition comprising an anti-neoplastic agent, such that the neoplastic disease is treated.  
     
     
         42 . The method of  claim 41  wherein the narrowing or obstruction is a tumor.  
     
     
         43 . The method of  claim 41  wherein the disease is a male reproductive tract disease.  
     
     
         44 . The method of  claim 43  wherein the male reproductive tract disease is testicular cancer, cancer of the epididymus, a tumor of the vas deferens, or prostatic cancer.  
     
     
         45 . The method of  claim 41  wherein the disease is a female reproductive tract disease.  
     
     
         46 . The method of  claim 45  wherein the female reproductive tract disease is auterine cancer, cervical cancer, vaginal cancer or a malignancy of the fallopian tubes.  
     
     
         47 . The method of  claim 41  wherein the disease is a gastrointestinal tract disease, a biliary tract disease, a urinary tract disease, or a respiratory tract disease.  
     
     
         48 . The method of  claim 41  wherein the body passageway is selected from the group consisting of an esophagus, a stomach, a duodenum, a small intestine, a large intestine, biliary tracts, a ureter, a bladder, and a urethra.  
     
     
         49 . The method of  claim 41  wherein the body passageway is selected from the group consisting of fallopian tubes, uterus, vagina, and vas deferens.  
     
     
         50 . The method of  claim 41  wherein the body passageway is selected from the group consisting of lacrimal ducts, trachea, bronchi, bronchiole, nasal airways, eustachian tubes, and an external auditory canal.  
     
     
         51 . The method of  claim 41  wherein the anti-neoplastic agent is an anti-proliferative agent.  
     
     
         52 . The method of  claim 41  wherein the anti-neoplastic agent is an anti-angiogenic factor.  
     
     
         53 . The method of  claim 41  wherein the anti-neoplastic agent disrupts microtubule function.  
     
     
         54 . The method of  claim 41  wherein the anti-neoplastic agent is paclitaxel or an analogue or derivative thereof.  
     
     
         55 . The method of  claim 41  wherein the anti-neoplastic agent is paclitaxel.  
     
     
         56 . The method of  claim 41  wherein the anti-neoplastic agent is an analogue or derivative of paclitaxel.  
     
     
         57 . The method of  claim 41  wherein the anti-neoplastic agent is estradiol.  
     
     
         58 . The method of  claim 41  wherein the anti-neoplastic agent is carboplatin.  
     
     
         59 . The method of  claim 41  wherein the anti-neoplastic agent is doxorubicin.  
     
     
         60 . The method of  claim 41  wherein the anti-neoplastic agent is 5-fluorouracil.  
     
     
         61 . The method of  claim 41  wherein the composition is biodegradable.  
     
     
         62 . The method of  claim 41  wherein the composition is non-biodegradable.  
     
     
         63 . The method of  claim 41  wherein the composition further comprises a polymer.  
     
     
         64 . The method of  claim 63  wherein the polymer is biodegradable.  
     
     
         65 . The method of  claim 63  wherein the polymer is non-biodegradable.  
     
     
         66 . The method of  claim 41  wherein the composition further comprises a copolymer of lactic acid and glycolic acid.  
     
     
         67 . The method of  claim 41  wherein the composition further comprises a poly(caprolactone).  
     
     
         68 . The method of  claim 41  wherein the composition further comprises a poly(lactic acid).  
     
     
         69 . The method of  claim 41  wherein the composition further comprises a copolymer of poly(lactic acid) and poly(caprolactone)  
     
     
         70 . The method of  claim 41  wherein the composition further comprises a poly(ethylene-vinyl acetate).  
     
     
         71 . The method of  claim 41  wherein the composition further comprises a polyester.  
     
     
         72 . The method of  claim 41  wherein the composition further comprises a polyurethane.  
     
     
         73 . The method of  claim 41  wherein the composition further comprises a polyanhydride.  
     
     
         74 . The method of  claim 41  wherein the composition further comprises a gelatin.  
     
     
         75 . The method of  claim 41  wherein the composition is in the form of a paste.  
     
     
         76 . The method of  claim 41  wherein the composition is in the form of a film.  
     
     
         77 . The method of  claim 41  wherein the composition is in the form of a spray.  
     
     
         78 . The method of  claim 41  wherein the composition comprises microspheres having an average size ranging from about 0.5 μm to 200 μm.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.